Progress in tuberculosis vaccine development

Current Opinion in Immunology

Volumn 18, Issue 4, 2006, Pages 438-448

  Baumann, Sven ^a   Eddine, Ali Nasser ^a   Kaufmann, Stefan HE ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIGEN; ANTIGEN 85A; ANTIGEN 85B; BCG VACCINE; CANCER ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; FAS ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 17; INTERLEUKIN 23; LISTERIOLYSIN; LIVE VACCINE; MYCOBACTERIUM ANTIGEN; PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANTIGENICITY; CELL MIGRATION; CELLULAR IMMUNITY; DRUG DESIGN; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MEMORY T LYMPHOCYTE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUBERCULOSIS; VIRAL GENE THERAPY;

HUMANS; INTERLEUKIN-15; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-23 SUBUNIT P19; INTERLEUKIN-7; INTERLEUKINS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 33745358909     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2006.05.016     Document Type: Review

References (110)

1. Kaufmann S.H. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol 26 (2005) 660-667
2. Young D., and Dye C. The development and impact of tuberculosis vaccines. Cell 124 (2006) 683-687
3. Basaraba R.J., Izzo A.A., Brandt L., and Orme I.M. Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine 24 (2006) 280-286
4. Nasser Eddine A., and Kaufmann S.H. Improved protection by recombinant BCG. Microbes Infect 7 (2005) 939-946
5. Sambandamurthy V.K., and Jacobs Jr. W.R. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect 7 (2005) 955-961
6. Kamath A.T., Fruth U., Brennan M.J., Dobbelaer R., Hubrechts P., Ho M.M., Mayner R.E., Thole J., Walker K.B., Liu M., et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23 (2005) 3753-3761
7. Fruth U., and Young D. Prospects for new TB vaccines: stop TB working group on TB vaccine development. Int J Tuberc Lung Dis 8 (2004) 151-155
8. Horwitz M.A. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect 7 (2005) 947-954
9. Horwitz M.A., and Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 71 (2003) 1672-1679
10. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Eddine A.N., Mann P., Goosmann C., Bandermann S., Smith D., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115 (2005) 2472-2479. The authors equipped an urease C-deficient BCG with the membrane-perforating listeriolysin of Listeria monocytogenes. This recombinant BCG shows improved protection against M. tuberculosis, including a hypervirulent strain of the 'Beijing/W' family. Listeriolysin not only promotes antigen translocation into the cytoplasm but also apoptosis of infected macrophages, which leads to crosspresentation of mycobacterial antigens and subsequently enhanced T cell-mediated immunity.
11. D'Souza S., Rosseels V., Romano M., Tanghe A., Denis O., Jurion F., Castiglione N., Vanonckelen A., Palfliet K., and Huygen K. Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect Immun 71 (2003) 483-493
12. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 97 (2000) 13853-13858
13. Reed S.G., Alderson M.R., Dalemans W., Lobet Y., and Skeiky Y.A. Prospects for a better vaccine against tuberculosis. Tuberculosis (Edinb) 83 (2003) 213-219
14. Hess J., Miko D., Catic A., Lehmensiek V., Russell D.G., and Kaufmann S.H. Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci USA 95 (1998) 5299-5304
15. Glomski I.J., Gedde M.M., Tsang A.W., Swanson J.A., and Portnoy D.A. The Listeria monocytogenes hemolysin has an acidic pH optimum to compartmentalize activity and prevent damage to infected host cells. J Cell Biol 156 (2002) 1029-1038
16. Glynn J.R., Whiteley J., Bifani P.J., Kremer K., and van Soolingen D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis 8 (2002) 843-849
17. van der Zanden A.G.M., Kremer K., Schouls L.M., Caimi K., Cataldi A., Hulleman A., Nagelkerke N.J.D., and van Soolingen D. Improvement of differentiation and interpretability of spoligotyping for Mycobacterium tuberculosis complex isolates by introduction of new spacer oligonucleotides. J Clin Microbiol 40 (2002) 4628-4639
18. Kaplan G. Rational vaccine development - a new trend in tuberculosis control. N Engl J Med 353 (2005) 1624-1625
19. Kaufmann S.H. Immunity to intracellular bacteria. Annu Rev Immunol 11 (1993) 129-163
20. + T cells in vivo and induces protection against M. tuberculosis infection. These apoptotic vesicles display potent adjuvant activity by stimulating through Toll-like receptors.
21. Rogers H.W., Callery M.P., Deck B., and Unanue E.R. Listeria monocytogenes induces apoptosis of infected hepatocytes. J Immunol 156 (1996) 679-684
22. Andersen P. TB vaccines: progress and problems. Trends Immunol 22 (2001) 160-168
23. Roberts A.D., Sonnenberg M.G., Ordway D.J., Furney S.K., Brennan P.J., Belisle J.T., and Orme I.M. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology 85 (1995) 502-508
24. McShane H., Pathan A.A., Sander C.R., Goonetilleke N.P., Fletcher H.A., and Hill A.V. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 85 (2005) 47-52
25. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., Fletcher H.A., and Hill A.V. Recombinant modified vaccinia virus ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 (2004) 1240-1244
26. Goonetilleke N.P., McShane H., Hannan C.M., Anderson R.J., Brookes R.H., and Hill A.V. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus ankara. J Immunol 171 (2003) 1602-1609
27. McShane H. Developing an improved vaccine against tuberculosis. Expert Rev Vaccines 3 (2004) 299-306
28. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect Immun 73 (2005) 4676-4683
29. Langermans J.A., Doherty T.M., Vervenne R.A., van der Laan T., Lyashchenko K., Greenwald R., Agger E.M., Aagaard C., Weiler H., van Soolingen D., et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23 (2005) 2740-2750
30. Olsen A.W., Williams A., Okkels L.M., Hatch G., and Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 72 (2004) 6148-6150
31. Doherty T.M., Olsen A.W., Weischenfeldt J., Huygen K., D'Souza S., Kondratieva T.K., Yeremeev V.V., Apt A.S., Raupach B., Grode L., et al. Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. J Infect Dis 190 (2004) 2146-2153
32. Lingnau K., Egyed A., Schellack C., Mattner F., Buschle M., and Schmidt W. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine 20 (2002) 3498-3508
33. Peppoloni S., Ruggiero P., Contorni M., Morandi M., Pizza M., Rappuoli R., Podda A., and Del Giudice G. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev Vaccines 2 (2003) 285-293
34. Orme I.M. Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 24 (2006) 2-19
35. Brandt L., Skeiky Y.A., Alderson M.R., Lobet Y., Dalemans W., Turner O.C., Basaraba R.J., Izzo A.A., Lasco T.M., Chapman P.L., et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72 (2004) 6622-6632
36. Tsenova L., Harbacheuski R., Moreira A.L., Ellison E., Dalemans W., Alderson M.R., Mathema B., Reed S.G., Skeiky Y.A., and Kaplan G. Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect Immun 74 (2006) 2392-2401
37. Lindblad E.B., Elhay M.J., Silva R., Appelberg R., and Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 65 (1997) 623-629
38. Mattner F., Fleitmann J.K., Lingnau K., Schmidt W., Egyed A., Fritz J., Zauner W., Wittmann B., Gorny I., Berger M., et al. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens. Cancer Res 62 (2002) 1477-1480
39. Fritz J.H., Brunner S., Birnstiel M.L., Buschle M., Gabain A., Mattner F., and Zauner W. The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens. Vaccine 22 (2004) 3274-3284
40. Braff M.H., Bardan A., Nizet V., and Gallo R.L. Cutaneous defense mechanisms by antimicrobial peptides. J Invest Dermatol 125 (2005) 9-13
41. Skeiky Y.A., Alderson M.R., Ovendale P.J., Guderian J.A., Brandt L., Dillon D.C., Campos-Neto A., Lobet Y., Dalemans W., Orme I.M., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172 (2004) 7618-7628
42. Kita Y., Tanaka T., Yoshida S., Ohara N., Kaneda Y., Kuwayama S., Muraki Y., Kanamaru N., Hashimoto S., Takai H., et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 23 (2005) 2132-2135
43. Bhatt K., Hickman S.P., and Salgame P. Cutting edge: a new approach to modeling early lung immunity in murine tuberculosis. J Immunol 172 (2004) 2748-2751
44. Ribeiro-Rodrigues R., Resende Co T., Rojas R., Toossi Z., Dietze R., Boom W.H., Maciel E., and Hirsch C.S. A role for CD4CD25 T cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol 144 (2006) 25-34
45. Smits H.H., van Beelen A.J., Hessle C., Westland R., de Jong E., Soeteman E., Wold A., Wierenga E.A., and Kapsenberg M.L. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. Eur J Immunol 34 (2004) 1371-1380
46. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., and Lanzavecchia A. Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6 (2005) 769-776
47. McKenzie B.S., Kastelein R.A., and Cua D.J. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 27 (2006) 17-23
48. + T cells into Th cells that produce IL-17 are examined, characterizing this unique Th lineage that regulates tissue inflammation and has been linked to autoimmune diseases. This cytokine could be involved in immunity to pulmonary tuberculosis.
49. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., and Weaver C.T. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6 (2005) 1123-1132
50. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., and Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201 (2005) 233-240
51. Seiler P., Aichele P., Bandermann S., Hauser A.E., Lu B., Gerard N.P., Gerard C., Ehlers S., Mollenkopf H.J., and Kaufmann S.H. Early granuloma formation after aerosol Mycobacterium tuberculosis infection is regulated by neutrophils via CXCR3-signaling chemokines. Eur J Immunol 33 (2003) 2676-2686
52. Aleman M., Schierloh P., de la Barrera S.S., Musella R.M., Saab M.A., Baldini M., Abbate E., and Sasiain M.C. Mycobacterium tuberculosis triggers apoptosis in peripheral neutrophils involving toll-like receptor 2 and p38 mitogen protein kinase in tuberculosis patients. Infect Immun 72 (2004) 5150-5158
53. Pedrosa J., Saunders B.M., Appelberg R., Orme I.M., Silva M.T., and Cooper A.M. Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice. Infect Immun 68 (2000) 577-583
54. Happel K.I., Lockhart E.A., Mason C.M., Porretta E., Keoshkerian E., Odden A.R., Nelson S., and Ramsay A.J. Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs. Infect Immun 73 (2005) 5782-5788
55. Wozniak T.M., Ryan A.A., Triccas J.A., and Britton W.J. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect Immun 74 (2006) 557-565
56. Khader S.A., Pearl J.E., Sakamoto K., Gilmartin L., Bell G.K., Jelley-Gibbs D.M., Ghilardi N., deSauvage F., and Cooper A.M. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 175 (2005) 788-795
57. Kaufmann S.H.E., and McMichael A.J. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 11 (2005) S33-S44
58. Winau F., Hegasy G., Kaufmann S.H., and Schaible U.E. No life without death-apoptosis as prerequisite for T cell activation. Apoptosis 10 (2005) 707-715
59. Schaible U.E., Winau F., Sieling P.A., Fischer K., Collins H.L., Hagens K., Modlin R.L., Brinkmann V., and Kaufmann S.H. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 9 (2003) 1039-1046
60. van Crevel R., Ottenhoff T.H., and van der Meer J.W. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev 15 (2002) 294-309
61. + dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 195 (2002) 1289-1302
62. Ochsenbein A.F., Sierro S., Odermatt B., Pericin M., Karrer U., Hermans J., Hemmi S., Hengartner H., and Zinkernagel R.M. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411 (2001) 1058-1064
63. Freigang S., Egger D., Bienz K., Hengartner H., and Zinkernagel R.M. Endogenous neosynthesis vs. cross-presentation of viral antigens for cytotoxic T cell priming. Proc Natl Acad Sci USA 100 (2003) 13477-13482
64. Zinkernagel R.M. On cross-priming of MHC class I-specific CTL: rule or exception?. Eur J Immunol 32 (2002) 2385-2392
65. Thomas A.M., Santarsiero L.M., Lutz E.R., Armstrong T.D., Chen Y.C., Huang L.Q., Laheru D.A., Goggins M., Hruban R.H., and Jaffee E.M. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 200 (2004) 297-306
66. Storni T., and Bachmann M.F. Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison. J Immunol 172 (2004) 6129-6135
67. Ackerman A.L., Kyritsis C., Tampe R., and Cresswell P. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc Natl Acad Sci USA 100 (2003) 12889-12894
68. Janda J., Schoneberger P., Skoberne M., Messerle M., Russmann H., and Geginat G. Cross-presentation of Listeria-derived CD8 T cell epitopes requires unstable bacterial translation products. J Immunol 173 (2004) 5644-5651
69. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
70. Yrlid U., and Wick M.J. Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells. J Exp Med 191 (2000) 613-624
71. Weinrauch Y., and Zychlinsky A. The induction of apoptosis by bacterial pathogens. Annu Rev Microbiol 53 (1999) 155-187
72. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
73. Sauter B., Albert M.L., Francisco L., Larsson M., Somersan S., and Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191 (2000) 423-434
74. Blachere N.E., Darnell R.B., and Albert M.L. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol 3 (2005) e185
75. Park J.S., Tamayo M.H., Gonzalez-Juarrero M., Orme I.M., and Ordway D.J. Virulent clinical isolates of Mycobacterium tuberculosis grow rapidly and induce cellular necrosis but minimal apoptosis in murine macrophages. J Leukoc Biol 79 (2006) 80-86
76. Lee J., Remold H.G., Ieong M.H., and Kornfeld H. Macrophage apoptosis in response to high intracellular burden of Mycobacterium tuberculosis is mediated by a novel caspase-independent pathway. J Immunol 176 (2006) 4267-4274
77. Bocchino M., Galati D., Sanduzzi A., Colizzi V., Brunetti E., and Mancino G. Role of mycobacteria-induced monocyte/macrophage apoptosis in the pathogenesis of human tuberculosis. Int J Tuberc Lung Dis 9 (2005) 375-383
78. Restifo N.P. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr Opin Immunol 12 (2000) 597-603
79. Ludwig D.L., Pereira D.S., Zhu Z., Hicklin D.J., and Bohlen P. Monoclonal antibody therapeutics and apoptosis. Oncogene 22 (2003) 9097-9106
80. Chattergoon M.A., Kim J.J., Yang J.S., Robinson T.M., Lee D.J., Dentchev T., Wilson D.M., Ayyavoo V., and Weiner D.B. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nat Biotechnol 18 (2000) 974-979
81. Sasaki S., Xin K.Q., Okudela K., Okuda K., and Ishii N. Immunomodulation by apoptosis-inducing caspases for an influenza DNA vaccine delivered by gene gun. Gene Ther 9 (2002) 828-831
82. Sasaki S., Amara R.R., Oran A.E., Smith J.M., and Robinson H.L. Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat Biotechnol 19 (2001) 543-547
83. Lee K.D., Oh Y.K., Portnoy D.A., and Swanson J.A. Delivery of macromolecules into cytosol using liposomes containing hemolysin from Listeria monocytogenes. J Biol Chem 271 (1996) 7249-7252
84. Reed M.B., Domenech P., Manca C., Su H., Barczak A.K., Kreiswirth B.N., Kaplan G., and Barry III C.E. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431 (2004) 84-87
85. Hirsh A.E., Tsolaki A.G., DeRiemer K., Feldman M.W., and Small P.M. Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proc Natl Acad Sci USA 101 (2004) 4871-4876
86. Belkaid Y., and Rouse B.T. Natural regulatory T cells in infectious disease. Nat Immunol 6 (2005) 353-360
87. Mittrucker H.W., and Kaufmann S.H. Mini-review: regulatory T cells and infection: suppression revisited. Eur J Immunol 34 (2004) 306-312
88. Guyot-Revol V., Innes J.A., Hackforth S., Hinks T., and Lalvani A. Regulatory T cells are expanded in blood and disease sites in tuberculosis patients. Am J Respir Crit Care Med 173 (2006) 803-810
89. Bonecini-Almeida M.G., Ho J.L., Boechat N., Huard R.C., Chitale S., Doo H., Geng J., Rego L., Lazzarini L.C., Kritski A.L., et al. Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis. Infect Immun 72 (2004) 2628-2634
90. Allen S.S., Cassone L., Lasco T.M., and McMurray D.N. Effect of neutralizing transforming growth factor beta1 on the immune response against Mycobacterium tuberculosis in guinea pigs. Infect Immun 72 (2004) 1358-1363
91. Kaufmann S.H. How can immunology contribute to the control of tuberculosis?. Nat Rev Immunol 1 (2001) 20-30
92. Junqueira-Kipnis A.P., Turner J., Gonzalez-Juarrero M., Turner O.C., and Orme I.M. Stable T-cell population expressing an effector cell surface phenotype in the lungs of mice chronically infected with Mycobacterium tuberculosis. Infect Immun 72 (2004) 570-575
93. Dudani R., Chapdelaine Y., Faassen H.H., Smith D.K., Shen H., Krishnan L., and Sad S. Multiple mechanisms compensate to enhance tumor-protective CD8(+) T cell response in the long-term despite poor CD8(+) T cell priming initially: comparison between an acute versus a chronic intracellular bacterium expressing a model antigen. J Immunol 168 (2002) 5737-5745
94. Jung Y.J., Ryan L., LaCourse R., and North R.J. Properties and protective value of the secondary versus primary T helper type 1 response to airborne Mycobacterium tuberculosis infection in mice. J Exp Med 201 (2005) 1915-1924
95. de Bree G.J., van Leeuwen E.M., Out T.A., Jansen H.M., Jonkers R.E., and van Lier R.A. Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung. J Exp Med 202 (2005) 1433-1442
96. van Faassen H., Saldanha M., Gilbertson D., Dudani R., Krishnan L., and Sad S. Reducing the stimulation of CD8+ T cells during infection with intracellular bacteria promotes differentiation primarily into a central (CD62LhighCD44high) subset. J Immunol 174 (2005) 5341-5350
97. Botha T., and Ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 171 (2003) 3110-3118
98. Andersen P., and Smedegaard B. CD4(+) T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. Infect Immun 68 (2000) 621-629
99. Bevan M.J. Immunology: remembrance of things past. Nature 420 (2002) 748-749
100. + T cells and T-cell exhaustion in mice chronically infected with lymphocytic choriomeningitis virus (LCMV). The identification of a specific mechanism of T-cell exhaustion defines a potentially effective immunological strategy for the treatment of chronic infections including tuberculosis.
101. Jimenez-Martinez M.C., Linares M., Baez R., Montano L.F., Martinez-Cairo S., Gorocica P., Chavez R., Zenteno E., and Lascurain R. Intracellular expression of interleukin-4 and interferon-gamma by a Mycobacterium tuberculosis antigen-stimulated CD4+ CD57+ T-cell subpopulation with memory phenotype in tuberculosis patients. Immunology 111 (2004) 100-106
102. Surh C.D., and Sprent J. Regulation of mature T cell homeostasis. Semin Immunol 17 (2005) 183-191
103. Prlic M., Lefrancois L., and Jameson S.C. Multiple choices: regulation of memory CD8 T cell generation and homeostasis by interleukin (IL)-7 and IL-15. J Exp Med 195 (2002) F49-F52
104. Lazarevic V., Yankura D.J., DiVito S.J., and Flynn J.L. Induction of Mycobacterium tuberculosis-specific primary and secondary T-cell responses in interleukin-15-deficient mice. Infect Immun 73 (2005) 2910-2922
105. + T cell effector activities. These results show adjuvant activity of IL-15 and demonstrate that IL-7 also serves as potent vaccine adjuvant.
106. Umemura M., Nishimura H., Saito K., Yajima T., Matsuzaki G., Mizuno S., Sugawara I., and Yoshikai Y. Interleukin-15 as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus calmette-guerin vaccination. Infect Immun 71 (2003) 6045-6048
107. Chapdelaine Y., Smith D.K., Pedras-Vasconcelos J.A., Krishnan L., and Sad S. Increased CD8+ T cell memory to concurrent infection at the expense of increased erosion of pre-existing memory: the paradoxical role of IL-15. J Immunol 171 (2003) 5454-5460
108. + effector and memory T cell generation. Nat Immunol 4 (2003) 835-842
109. + T cells.
110. Irwin S.M., Izzo A.A., Dow S.W., Skeiky Y.A., Reed S.G., Alderson M.R., and Orme I.M. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun 73 (2005) 5809-5816